Code | CSB-RA246354A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IHC | 1:50-1:200 |
The MAPT recombinant monoclonal antibody was developed using protein and DNA recombinant technology. Initially, mice were injected with a synthetic peptide from human MAPT, and after a specific duration, spleen cells were aseptically extracted. The total RNA of the spleen cells was isolated, and the cDNA was synthesized from RNA reverse transcription, which served as the PCR template to amplify the MAPT antibody gene. The resulting MAPT antibody gene was then integrated into a vector, which was transfected into host cells and cultured. Subsequently, the MAPT recombinant monoclonal antibody was purified from the cell culture supernatant through affinity chromatography and extensively validated. This antibody can be used for ELISA and IHC experiments to detect the human MAPT protein.
The MAPT protein is primarily involved in stabilizing microtubules in neuronal cells. MAPT binds to microtubules and promotes their assembly and stability by crosslinking and bundling them together. It also helps to regulate the dynamics of microtubules by promoting their growth and preventing their disassembly. MAPT is involved in signaling pathways that control cell survival, growth, and differentiation. Mutations in the MAPT gene or alterations in MAPT protein expression have been associated with several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and frontotemporal dementia.
There are currently no reviews for this product.